toripalimab   Click here for help

GtoPdb Ligand ID: 12989

Synonyms: JS-001 | JS001 | Loqtorzi® | toripalimab-tpzi
Approved drug Immunopharmacology Ligand
toripalimab is an approved drug (FDA (2023), EMA (2024))
Compound class: Antibody
Comment: Toripalimab (JS001) is an anti-programmed cell death protein-1 (PD-1) immuno-oncology biologic [3]. It blocks the inhibitory immune checkpoint interaction between PD-1 and its ligands and reinstates a cytotoxic T cell response against tumour cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Toripalimab was advanced to clinical studies in an extensive range of advanced tumour types. It was FDA approved to treat metastatic/recurrent, locally advanced or recurrent unresectable/metastatic nasopharyngeal carcinoma (NPC) in October 2023.
Click here to link to ClinicalTrials.gov's full list of toripalimab/JS001 studies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02838823 Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer Phase 1 Interventional Shanghai Junshi Bioscience Co., Ltd. 1
NCT04398056 Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma Phase 2 Interventional Sun Yat-sen University This study found evidence of toripalimab efficacy in patients with de novo metastatic nasopharyngeal carcinoma in combination with sequential chemoradiotherapy. Results were indicative of potential to utilise this chemo-radioimmunotherapy regimen as a first-line treatment for this indication. 2
NCT03581786 The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer Phase 3 Interventional Shanghai Junshi Bioscience Co., Ltd. The JUPITER-02 study: reported clinically meaningful progression-free survival and overall survival benefits with toripalimab plus gemcitabine-cisplatin chemotherapy as first-line treatment for recurrent/metastatic nasopharyngeal carcinoma, compared to chemotherapy alone. 4
NCT04280822 Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma Phase 3 Interventional Henan Cancer Hospital 5